Boston Therapeutics, Inc. Retains MZ Group as Its Investor Relations Advisor

MANCHESTER, NH--(Marketwire - June 11, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that it has retained MZ Group as its investor relations advisor.

MZ Group will assist Boston Therapeutics with communicating its corporate, financial and investor-related developments to shareholders and investors, while building a strong public brand and investor base. Ted Haberfield, Scott Powell and the MZ Group team will be advising the Company in multiple facets of corporate and financial communications.

“We are excited to partner with MZ Group,” said Ken Tassey, President of Boston Therapeutics. “With solid progress on our two main products, SUGARDOWN® and PAZ320, we look forward to telling our story to investors in the U.S. and internationally. As we expand our corporate and product branding and investor relations efforts, we believe MZ Group provides the global reach and an established track record that will help us increase awareness and the role that our products play in improving people’s lives. MZ’s strong relationships with retail and institutional investors in North America and Asia in particular make them an ideal investor relations partner,” concluded Mr. Tassey.

Ted Haberfield, President of MZ Group North America, stated: “Boston Therapeutics has several compelling products at various stages of development and a diversified go-to-market strategy for the multi-billion-dollar diabetes therapeutics market. U.S. investors are looking for companies developing cutting edge consumer and pharmaceutical products that address the esalacting epidemic of diabetes. With its recent OTCQB listing and SUGARDOWN®'s first sales, we believe the investment thesis for Boston Therapeutics is very compelling,” concluded Mr. Haberfield.

About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, is a leader in the field of complex carbohydrates, a specialized field involving understanding the importance of the role that carbohydrates play in biochemistry and progression of diseases. The Company’s initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement designed to moderate post-meal blood glucose, and IPOXYN™, a systemic, injectable complex carbohydrate-based oxygen therapeutic for limb ischemia. More information is available at www.bostonti.com.

About MZ Group
MZ Group, subsidiary of @titude Global, a multinational company and the world’s largest independent global investor relations consulting firm, provides investor relations, corporate communications, market intelligence, corporate governance and technology products and services. Founded in 1999, MZ Group focuses on innovation and personalized services, supported by its exclusive “one-stop-shop” business model. With offices in São Paulo, New York, Chicago, San Diego, Vancouver, Hong Kong, Beijing, Shanghai, Taipei and Mumbai, MZ has approximately 350 professionals who serve over 580 clients in 12 countries. For more information, please visit www.mz-ir.com.

Forward-Looking Statements

The Company’s views as of the date of this press release should not be relied upon to represent the Company’s views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company’s views to change, the Company disclaims any obligation to update such forward-looking statements.

More information about those risks and uncertainties is contained and discussed in the Company’s most recent quarterly or annual report and in the Company’s other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company’s views as of the date of this press release and should not be relied upon to represent the Company’s views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company’s views to change, the Company disclaims any obligation to update such forward-looking statements.